株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中枢神経系障害向け遺伝子治療の世界市場:2019年~2023年

Global Gene Therapy for CNS Disorders Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 823144
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.90円で換算しております。
Back to Top
中枢神経系障害向け遺伝子治療の世界市場:2019年~2023年 Global Gene Therapy for CNS Disorders Market 2019-2023
出版日: 2019年03月28日 ページ情報: 英文 119 Pages
概要

特別な薬剤の指定の増加は、今後数年間、市場が継続的に成長するための重要な要素の1つと見込まれています。迅速な承認を受ける役に立つよう、ベンダーは新規遺伝子治療のための特別な薬物指定を受けています。一部の市場関係者は、臨床研究に様々な税制上の優遇措置を与えられたオーファンドラッグ指定さえも提供しています。その結果、規制機関からの特別な薬物指定の増加によって、今後数年間でCNS障害向け遺伝子治療市場の成長が促進されるでしょう。 Technavioのアナリストは、世界のCNS障害向け遺伝子治療市場が2023年までにおよそ27%のCAGRで成長すると予測しています。

当レポートでは、世界の中枢神経系障害向け遺伝子治療市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 パイプライン

第7章 市場セグメンテーション:症状別

  • 市場セグメンテーション:症状別
  • 症状別比較:市場規模および予測(2018年~2023年)
  • SMA
  • その他
  • 市場機会:症状別

第8章 顧客情勢

第9章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第10章 意思決定の枠組み

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics

第15章 付録

  • 調査方法
  • 略語のリスト

第16章 TECHNAVIOについて

図表
  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global gene therapy for CNS disorders market pipeline: Overview
  • Exhibit 18: Global gene therapy for CNS disorders market pipeline: Snapshot
  • Exhibit 19: Indication - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by indication
  • Exhibit 21: SMA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: SMA - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by indication
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: Biogen - Vendor overview
  • Exhibit 50: Biogen - Business segments
  • Exhibit 51: Biogen - Organizational developments
  • Exhibit 52: Biogen - Geographic focus
  • Exhibit 53: Biogen - Key offerings
  • Exhibit 54: Biogen - Key customers
  • Exhibit 55: bluebird bio, Inc. - Vendor overview
  • Exhibit 56: bluebird bio, Inc. - Product segments
  • Exhibit 57: bluebird bio, Inc. - Organizational developments
  • Exhibit 58: bluebird bio, Inc. - Key offerings
  • Exhibit 59: bluebird bio, Inc. - Key customers
  • Exhibit 60: Novartis AG - Vendor overview
  • Exhibit 61: Novartis AG - Business segments
  • Exhibit 62: Novartis AG - Organizational developments
  • Exhibit 63: Novartis AG - Geographic focus
  • Exhibit 64: Novartis AG - Segment focus
  • Exhibit 65: Novartis AG - Key offerings
  • Exhibit 66: Novartis AG - Key customers
  • Exhibit 67: Pfizer Inc. - Vendor overview
  • Exhibit 68: Pfizer Inc. - Business segments
  • Exhibit 69: Pfizer Inc. - Organizational developments
  • Exhibit 70: Pfizer Inc. - Geographic focus
  • Exhibit 71: Pfizer Inc. - Segment focus
  • Exhibit 72: Pfizer Inc. - Key offerings
  • Exhibit 73: Pfizer Inc. - Key customers
  • Exhibit 74: Voyager Therapeutics - Vendor overview
  • Exhibit 75: Voyager Therapeutics - Business segments
  • Exhibit 76: Voyager Therapeutics - Organizational developments
  • Exhibit 77: Voyager Therapeutics - Key offerings
  • Exhibit 78: Voyager Therapeutics - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
目次
Product Code: IRTNTR31112

About this market

The increase in special drug designations is one of the key factors anticipated to witness continuous growth in the forthcoming years. Vendors are receiving special drug designations for their novel gene therapies to help in receiving quicker approval. Some market players are even offering the orphan drug designation with various tax benefits on their clinical researches. As a result, the rising number of special drug designations from the regulatory bodies will drive the gene therapy for CNS disorders market growth in the forthcoming years. Technavio's analysts have predicted that the gene therapy for CNS disorders market will register a CAGR of nearly 27% by 2023.

Market Overview

Increase in special drug designations

One of the growth drivers of the global gene therapy for CNS disorders market is the increase in special drug designations. The increasing number of special drug designations from the regulatory bodies is expected to result in the quicker approval of gene therapy programs, which drives the growth of the market.

Uneven distribution of technology

One of the challenges in the growth of the global gene therapy for CNS disorders market is the Uneven distribution of technology. The lack of focus of major vendors on developing gene therapy for CNS disorders are expected to hinder the market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the gene therapy for CNS disorders market during 019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are developing advanced technologies that help in manufacturing gene therapies with superior efficacy for the treatment of various CNS indications. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • SMA - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

Back to Top